Objective: To develop and externally validate a prediction model for severe cisplatin associated acute kidney injury (CP-AKI).
Design: Multicenter cohort study.
Setting: Six geographically diverse major academic cancer centers across the US.
Introduction: Hyperthermic intraoperative cisplatin (HIOC) is associated with acute kidney injury (AKI). Administration of high-dose magnesium attenuates cisplatin-induced AKI (CP-AKI) in animal models but has not been rigorously examined in humans.
Methods: We tested the feasibility and safety of different doses of magnesium in mesothelioma patients receiving HIOC.